APAleksandr V. Parnas

Aleksandr V. Parnas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksandr V. Parnas has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimization of Response Dynamics Assessment for Targeted ¹⁷⁷Lu-PSMA Radioligand Therapy Using PET/CT, PSA, and SPECT/CT

    by A. V. Parnas, A. S. Krylov, A. V. Filimonov, V. V. Solomyany, V. S. Ilyakov, O. D. Baranova, A. A. Li, A. V. Klimov, А. В. Парнас, А. С. Крылов, et al.

    Purpose : To optimize the evaluation of response dynamics during PSMA-targeted radioligand therapy (RLT) ¹⁷⁷Lu-PSMA based on a comprehensive analysis of prostate-specific antigen (PSA), post-therapeutic single-photon emission computed tomography/ computed tomography (SPECT/CT), and positron emission tomography/computed tomography (PET/CT) with ¹⁸F-PSMA-1007 in patients with metastatic castration-resistant prostate cancer (mCRPC). Material and methods : A retrospective single-center study was conducted, including 78 patients with mCRPC who received 2 to 6 cycles of ¹⁷⁷Lu-PSMA-617 therapy. Monitoring included three levels: PSA dynamics (before each cycle), post-therapeutic SPECT/ CT (24 hours after each administration), and PET/CT with ¹⁸F-PSMA-1007 (baseline and after 2, 4, and 6 cycles). The dynamics of radiopharmaceutical uptake, SUV max values, and concordance between methods were assessed. The primary endpoint was progression-free survival (PFS) assessed by PET/CT. Results : The median PFS by PET/CT in the overall cohort was 9 months. Stratified by PET/CT dynamics after 2 cycles, median PFS was: positive dynamics — 14 months, divergent — 8 months, negative — 5 months (p30 % reduction in SUV max in bone lesions on SPECT/CT after the 1st cycle was associated with longer PFS (13.5 months vs. 5.5 months; p < 0.001). Concordance between PSA and PET/ CT was moderate (κ=0.44), with discordance observed in 17.9 % of cases. The highest concordance was between SPECT/CT and PET/ CT (κ=0.68-0.70). PSMA-negative progression was detected in 5 patients (6.4 %), with 4 of them showing decreasing or stable PSA levels. A >30 % reduction in SUV max in bone lesions on SPECT/CT after the 1st cycle was associated with longer PFS (13.5 months vs. 5.5 months; p < 0.001). No grade ≥3 adverse events were recorded. Conclusion : Combined monitoring (PSA + SPECT/CT after each cycle + PET/CT with ¹⁸F-PSMA-1007 every 2 cycles) is optimal for response assessment during ¹⁷⁷Lu-PSMA therapy. Isolated PSA assessment is insufficient due to high discordance with imaging methods. Post-therapeutic SPECT/CT allows outcome prediction, while PET/CT is essential for detecting PSMA-negative progression and making decisions on therapy continuation or cessation. The proposed three-level approach enables timely treatment individualization.

  • Open Access

    177Lu-PSMA therapy in patients with prostate cancer. “Holiday” strategy. Pilot study

    by Aleksandr V. Parnas, A. S. Krylov, B. M. Khakulova, A. V. Filimonov, A. I. Pronin, V. S. Ilyakov, A. A. Rumyantsev

    Aim. To evaluate the strategy of temporary interruption of prostate-specific membrane antigen (PSMA)-targeted therapy 177Lu-PSMA. Materials and methods. A retrospective observational study was conducted which included 30 patients divided into two groups: treatment group (n = 16) received 2 to 4 fractions of 177Lu-PSMA and switched to observation (“holiday”), and control group (n = 14) completed the standard 6 fractions. Prostate-specific antigen (PSA) reduction rates, progression-free survival (PFS), adverse event rate, and effect of combination therapy (177Lu-PSMA + enzalutamide) were evaluated. Results. In the first group, a decrease in PSA by more than 50 % was observed in 100 % of patients, in the second group in 92.3 %. The median PFS was 8 months in the first group and 6 months in the second. No serious adverse events ( grade II) were observed. Combination with enzalutamide was associated with improved PFS (median 12 months vs 6 months). Patients with poorly differentiated tumors (Gleason ≥9) and previous 223Ra therapy had worse prognosis (median PFS 5 months). Conclusion. Interruption of 177Lu-PSMA therapy after 2–4 fractions with subsequent continuation in case of progression is a promising strategy that allows balancing between efficacy and safety. This approach is especially relevant for patients with limited metastatic burden and high risk of hematological toxicity. However, given the limited and heterogeneous patient sample, a detailed study in a larger patient cohort is necessary.

  • Open Access

    Lipoma in the Left Brachiocephalic Vein on 18F-PSMA PET/CT 1007: a Clinical Case

    by A. V. Parnas, A. I. Pronin, P. E. Tulin, A. V. Filimonov, V. S. Ilyakov

    Lipomas of large central veins are rare. The most common localization of these tumors is the inferior vena cava (LVA), where they are found in about 0.5 % of the general population during contrast-enhanced computed tomography (CT). Currently, no clinical cases of lipomas in the brachiocephalic vein have been published in the literature, which would have been detected during PET/CT examination. Here is a clinical case of a patient with primary multiple metachronous tumor processes: prostate cancer, breast cancer, kidney cancer, that has undergone PET/CT scan with 18F - PSMA-1007.

  • Open Access

    Impressive response to 177Lu-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer refractory to apalutamide, docetaxel and metastasis-directed therapy

    by A. A. Li, T. M. Geliashvili, A. A. Rumyantsev, A. I. Pronin, A. S. Krylov, O. D. Baranova, A. V. Parnas, V. S. Ilyakov, D. A. Vorobyeva

    PSMA-targeted radionuclide therapy (PSMA – prostate-specific membrane antigen) based on the theranostic concept of “treat what we see and see what we treat” has proven to be a highly effective therapeutic modality for metastatic castration-resistant prostate cancer (mCRPC). We present an illustrative case of the effectiveness and prospects of this therapy in mCRPC. The patient aged 84 years underwent external beam radiation therapy (EBRT) to the prostate area, seminal vesicles, and regional lymph nodes at the stage of locally advanced prostate cancer (cT3aN1M0, stage IV). After 28 months of androgen deprivation therapy, castration-resistant stage of the disease was registered with multiple metastases in the bones and pelvic lymph nodes. In combination with ongoing androgen deprivation therapy, the following treatments were sequentially performed: metastasis-directed therapy through stereotactic radiotherapy to the bone lesions, apalutamide in combination with stereotactic radiotherapy to the bone and lymph node lesions, and 5 courses of docetaxel chemotherapy. Time to progression with these therapies did not exceed 6 months. From December 2022 to May 2023, 177Lu-PSMA-617 PSMA-targeted therapy was performed (4 courses with an interval of 6–8 weeks, average therapeutic activity 7.6 GBq). Treatment was suspended due to development of complete radiologic response and the absence of metabolic substrate for continuation of therapy as well as total prostate-specific antigen decrease from 17 ng/mL (December of 2022) to 0.01 ng/mL (June of 2023). Among the adverse effects, the development of grade 1 xerostomia was noted. At the follow-up examination in March 2024, ECOG (Eastern Cooperative Oncology Group) score was 0, total prostate-specific antigen level was 0.05 ng/mL, complete radiologic response according to positron emission tomography/computed tomography with 18F-PSMA-1007 was registered, time without progression was 15 months. Therefore, PSMA-targeted radioligand therapy with 177Lu-PSMA-617 was highly effective with low toxicity in an elderly patient with mCRPC refractory to standard drug therapy.


  • Open Access

    PET/CT with 18F-PSMA-1007 in Diagnostics of Metastatic Lesions of Clear-Cell Renal Cell Carcinoma in Comparison with 18F-FDG: Prospective Study

    by V. S. Ilyakov, A. I. Pronin, A. V. Parnas, A. S. Subbotin, A. S. Krylov, T. M. Geliashvili, E. V. Bezumova, O. V. Mehedova, N. I. Nesterova, V. B. Matveev

    Purpose: To demonstrate the capabilities of PET/CT with 18F-PSMA-1007 in comparison with 18F-FDG in the diagnostics of metastatic ccRCC.Material and methods: Ninety-seven patients with metastatic ccRCC were included in the study. Biopsy results of the primary tumor were available in all patients. Metastatic foci were confirmed by biopsy, follow-up and other diagnostic methods. All patients under went PET/CT with 18F-PSMA-1007 and 18F FDG.Results: A total of 1247 metastases were identified in 97 patients: 1002 — PSMA-positive, 245 — PSMA-negative, 694 — FDG-positive, and 553 — FDG-negative. The largest number of foci was found in the lungs (601 in 43 patients), bones (220 in 46 patients), and lymph nodes (166 in 34 patients).Sixty-two patients had more PSMA-positive foci compared with 18FDG, 32 had an equal number of foci, and 3 had more foci according to PET/CT with 18FDG.The sensitivity and specificity of 18F-PSMA-1007 in the diagnostics of ccRCC metastases were 80 % and 72 %, positive and negative predictive value were 87 % and 61 %, respectively.The sensitivity and specificity of 18F-FDG in the diagnostics of ccRCC metastases were 55 % and 54 %, positive and negative predictive value were 69 % and 41 %, respectively.The mean SUVmax difference between 18F-PSMA-1007 and 18FDG was 5.32, and the mean TBR difference was 5.66. Lung foci demonstrated significantly lower SUVmax and TBR for both RPs compared to other metastases.Discussion and conclusions. Data analysis demonstrates higher efficiency of 18F-PSMA-1007 compared to 18F-FDG in the diagnostics of ccRCC metastases. PET/CT with 18F-PSMA-1007 revealed a higher number of metastases, SUVmax and TBR in studies with 18F-PSMA-1007 are on average significantly higher than those with 18F FDG.PET/CT with 18F-PSMA-1007 demonstrates the lowest efficiency in the diagnosis of foci in the lungs up to 1 cm. It is feasible to analyze pulmonary foci and other metastases separately to exclude the influence of a large number of low-active and false-negative foci on statistical parameters.PET/CT with 18F-PSMA-1007 can be recommended for use in patients with suspected metastatic ccRCC as an alternative to routine diagnostic methods and PET/CT with 18F-FDG. The potential of 18F-PSMA-1007 in assessing the efficacy of systemic therapy requires further investigation.


  • PET/CT with 18F-PSMA-1007 in Diagnostics of Primary and Recurrent Lesions of Clear-cell Renal Cell Carcinoma in Comparison with 18F-FDG: Prospective Study

    by V. S. Ilyakov, A. I. Pronin, A. V. Parnas, A. S. Subbotin, A. S. Krylov, T. M. Geliashvili, E. V. Bezumova, O. V. Mehedova, N. I. Nesterova, V. B. Matveev

    Introduction: Attempts have been made to use various RPs, other than 18F-FDG in the diagnostics of renal cell carcinoma (RCC), with promising results demonstrated by PSMA-specific RPs, in particular 18F-PSMA-1007.A prospective study was conducted at N.N. Blokhin NMRCO to establish capabilities of PET/CT with 18F-FDG and 18F-PSMA-1007 in primary and recurrent ccRCC diagnostics.Material and methods: Forty-eight patients were included in the study, 28 with renal masses and 20 with suspected local recurrence of ccRCC. Biopsy results were available in all patients. All patients underwent PET/CT with 18F-PSMA-1007 and 18F-FDG.Results: Thirty-nine renal neoplasms were identified in 28 patients. 24 of 39 foci (21 patients) were PSMA-positive and 18 of 39 foci (16 patients) were FDG-positive. No false-positive foci were identified. The sensitivity, specificity, positive and negative predictive value in primary RCC were: for 18F-PSMA-1007 — 75, 100, 100 and 85 %, respectively; for 18FDG — 57, 100, 100 and 76 %, respectively. The SUVmax level of 18F-PSMA-1007 exceeded 18FDG in 27 of 28 patients (38 foci); the tumor/background ratio was higher in 16 of 28 patients (24 foci). Tumor thrombosis was detected in 6 patients (PSMA-positive 6 of 6, FDG-positive 5 of 6). PSMA-SUVmax levels in thrombi exceeded 18FDG in all patients, tumor/background ratio in 5 out of 6 patients. Local recurrence was detected in 13 of 20 patients (27 foci). 10 foci in the remaining 7 patients were considered as false positives. No false-negative results were obtained. Sensitivity, specificity, positive and negative predictive value in the diagnosis of local recurrence of ccPCC: 18F-PSMA-1007 — 100, 94, 81 and 100 %, respectively; 18FDG -100, 89, 68 and 100 %, respectively.SUVmax and tumor/background ratio were found to correlate with primary tumor and recurrent node sizes for both RPs.Discussion and conclusions: At the moment, the role of 18F-PSMA-1007 in RCC diagnostics has not been defined. We can note the high efficiency of this RP in the assessment of the primary focus and recurrence of ccRCC, its usage is justified in cases, when routine diagnostic methods do not give an unambiguous answer.The possibilities of 18F-PSMA-1007 in metastatic ccRCC diagnostics are of the greatest interest. A significant prospective material has been collected in our department, which will be the basis for further study of this RP in the diagnostics of metastatic ccRCC.


  • Features of PET/CT Description with 18F-Fluoroestradiol in Patients with Estrogen-Positive Breast Cancer

    by A. V. Parnas, A. I. Pronin, D. A. Ryabchikov, P. E. Tulin, A. S. Subbotin, V. S. Ilyakov, N. V. Cherepanova, Yu. I. Prokofiev

    Purpose: To study possible errors in the interpretation and analysis of PET/CT studies with 18F-FES performed in patients with estrogen receptor-positive breast tumors.Material and methods: Data PET/CT with 18F-FES from 140 PET patients were retrospectively analyzed from 2017 to 2023. The study included patients with histologically confirmed estrogen receptor-positive breast cancer, before the start of specific treat­ment, as well as when progression is detected or if a metastatic process is suspected at the initial examination stage.Results: Recommendations are given for the assessment and interpretation of various changes detected during PET/CT with 18F-FES in patients with estrogen receptor-positive breast cancer, which may cause difficulties in analyzing the results of the study.Conclusion: Although the PET/CT with 18F-FES in our country has not yet been widely introduced into clinical practice, in some institutions the study is carried out within the framework of scientific protocols and in complex cases of differential diagnosis. For a more correct interpretation of PET/CT with 18F-FES should take into account the clinical and morphological features in each clinical case.

  • Open Access

    PET/CT with 18F-FDG for TENIS Syndrome in a Patient with Bone Metastasis of Hurthle Cell Thyroid Cancer: a Clinical Case Report

    by A. A. Li, T. M. Geliashvili, E. A. Sushencov, A. V. Parnas, O. D. Baranova, M. O. Goncharov, V. S. Ilyakov, A. V. Puchnina

    A significant role in improving the prognosis of differentiated thyroid cancer (DTC) in the presence of bone metastases is determined by early diagnosis of metastases, timely and correctly selected treatment tactics for the patient. During dynamic follow-up of patients with DTC after combined treatment (thyroidectomy with radioiodine therapy) are determination of the level of oncomarkers (serum thyroglobulin and antibodies to thyroglobulin) and ultrasound diagnostic of the neck, scanning with radioactive iodine (if clinically indicated). In some cases, patients have TENIS-syndrome (Thyroglobulin Elevated Negative Iodine Scintigraphy, hereinafter TENIS-syndrome), characterized by high serum thyroglobulin level in blood and absence of radioactive iodine accumulation on post therapeutic scintigraphy. According to the research studies, PET/CT with 18F-FDG has high sensitivity and specificity (89 % and 72 %, respectively) in visualization of metastatic radioiodine refractory foci in TENIS-syndrome.This article presents a clinical case of a patient, a 52-year-old woman with Gurtle cell thyroid cancer (pT3aN0M0, stage I) with established TENIS syndrome. Thyroidectomy was performed in September 2019 and radioiodine therapy was performed in January 2022 due to suspected disease progression given high thyroglobulin levels. Given the absence of pathologic accumulation of 131I according to post-therapy radioiodine scanning, PET/CT with 18F-FDG was performed, which revealed a solitary metastasis in the left iliac bone (41×35×42 mm with SUVmax 17.25). In November 2022, radical treatment of the solitary bone metastasis was performed in the scope of resection of the left iliac bone with reconstructive-plastic component. According to the data of control examinations in June 2023, the patient has a complete biochemical and radiologic remission of the disease.

  • Open Access

    PET/CT with 18F-Fluoroestradiol in First Diagnosed Breast Cancer. A Pilot Study

    by A. V. Parnas, A. S. Subbotin, A. I. Pronin, P. E. Tulin, D. A. Ryabchikov, V. S. Ilyakov, N. V. Cherepanova, O. V. Mekhedova

       Purpose: To evaluate the informativity of PET/CT with 18F-FES in determining estrogen receptor (ER) positivity in breast tumor tissue, as well as in regional lymph nodes or distant metastatic foci.   Material and methods: The data of 30 patients who underwent PET/CT with 18F-FES performed at the stage of primary diagnosis were retrospectively analyzed. The study included patients before the start of specific treatment or on the background of neoadjuvant hormone therapy, with previously determined expression of ER according to the results of IGC. 14 patients underwent 18F-FDG PET/CT with 2–7 days difference between both PET/CT.   Results: In our study, the mean SUVmax value in the primary tumor focus was 4.8, the lowest SUVmax = 1.61, and the highest SUVmax = 18.86. 18F-FES accumulation considered suspicious for metastatic lesion in axillary lymph nodes on the affected side was detected in 16 patients (56 %), mean SUVmax = 5.2, lowest SUVmax = 0.99, highest SUVmax = 11.54. On subsequent histological examination, tumor changes in axillary lymph nodes were confirmed in 16/16 patients.   Conclusion: PET/CT with 18F-FES is a diagnostic method for noninvasive evaluation of ER expression in tumor foci, which can complement the data of traditional diagnostic methods and has a significant clinical potential. In our study, the results of PET/CT with 18F-FES coincided with the data of immunohistochemical study in 100 % of cases.

  • Open Access

    PSMA‑Targeted Radioligand Therapy with the Radiopharmaceutical 177Lu‑PSMA‑617 in a Patient with Metastatic Castration‑Resistant Prostate Cancer

    by T. M. Geliashvili, A. S. Krylov, P. I. Bliganov, B. I. Dolgushin, A. I. Pronin, A. S. Tyulyandina, A. V. Parnas, A. D. Ryzhkov, A. V. Pavlova

    The expression of prostate-specific membrane antigen (PSMA) on the surface of prostate cancer cells is increased with tumor progression, which is the basis for a theranostic approach in the treatment of these patients. The PSMA ligand, labeled with the therapeutic radionuclide lutetium-177 (177Lu), delivers 177Lu beta particle radiation to PSMA-expressing prostate cancer cells. Currently, PSMA-targeted radioligand therapy with the radiopharmaceutical 177Lu-PSMA-617 is approved for the therapy of patients with metastatic castration-resistant prostate cancer (mCRPC). We present a clinical case of successful use of this method of treatment in our center in a patient with mCRPC, progressing after two lines of therapy — hormone therapy with new generation of androgen signal inhibitors (abiraterone, enzalutamide) and chemotherapy with docetaxel.